Department of Medical Pathology, Hospital Universitario La Fe, Valencia, Spain.
Leuk Res. 2013 Dec;37(12):1690-6. doi: 10.1016/j.leukres.2013.09.015. Epub 2013 Sep 21.
The MYBL2 gene encodes a transcription factor implicated in cell proliferation and maturation whose amplification or overexpression has been associated with different human malignancies, suggesting that it could be implicated in tumorigenesis. We analyzed MYBL2 expression and its prognostic value in 291 patients with de novo acute myeloid leukemia (AML) and we also evaluated its association with microRNAs 29 and 30 families. MYBL2 expression in AML patients was increased relative to CD34+ cells. Moreover, MYBL2 overexpression was associated with lower expression of miR-30a (P=0.024), miR-30b (P=0.021) and miR-30c (P=0.009). Multivariate analysis showed that MYBL2 expression was an independent factor for disease-free survival (HR 3.0, 95% CI 1.5-6.0, P=0.002) and cumulative incidence of relapse (HR 2.6, 95% CI 1.2-5.6, P=0.015) in patients with an intermediate-risk karyotype. In conclusion, our data showed that MYBL2 expression analysis could be useful to define subgroups of patients with poor prognosis.
MYBL2 基因编码一种参与细胞增殖和成熟的转录因子，其扩增或过表达与多种人类恶性肿瘤相关，提示其可能与肿瘤发生有关。我们分析了 291 例初诊急性髓系白血病（AML）患者的 MYBL2 表达及其预后价值，并评估了其与 microRNAs 29 和 30 家族的关系。AML 患者的 MYBL2 表达相对于 CD34+细胞增加。此外，MYBL2 过表达与 miR-30a（P=0.024）、miR-30b（P=0.021）和 miR-30c（P=0.009）的表达降低相关。多变量分析显示，在中危核型患者中，MYBL2 表达是无病生存（HR 3.0，95%CI 1.5-6.0，P=0.002）和复发累积发生率（HR 2.6，95%CI 1.2-5.6，P=0.015）的独立因素。总之，我们的数据表明，MYBL2 表达分析可用于定义预后不良的患者亚组。
